Lexeo Therapeutics (LXEO) Q4 2025 earnings summary

Executive summary

• Advanced pivotal trial preparations for LX2006 in Friedreich Ataxia, with protocol and SAP submitted to FDA and study initiation on track for 1H 2026.

• Positive interim clinical data for LX2006 and LX2020, showing efficacy and safety in cardiac and neurologic measures.

• Strengthened leadership with new Chief Medical Officer and senior appointments to enhance cardiovascular expertise.

• Established research collaboration with Johnson & Johnson for targeted cardiac gene therapy delivery.

• Cash position of $246.6 million expected to fund operations into 2028.

Financial highlights

• Cash, cash equivalents, and investments totaled $246.6 million as of December 31, 2025, up from $128.5 million at year-end 2024.

• Research & Development expenses were $16.2 million for Q4 2025 (down from $18.4 million in Q4 2024) and $63.8 million for FY 2025 (down from $74.1 million in FY 2024).

• General & Administrative expenses were $6.9 million for Q4 2025 (down from $9.0 million in Q4 2024) and $45.5 million for FY 2025 (up from $31.7 million in FY 2024).

• Net loss was $20.9 million ($0.27/share) for Q4 2025, compared to $25.9 million ($0.78/share) in Q4 2024; FY 2025 net loss was $100.0 million ($1.86/share) vs. $98.3 million ($3.09/share) in FY 2024.

• $154 million equity financing executed in October 2025 to support pipeline development.

Outlook and guidance

• SUNRISE-FA 2 pivotal trial for LX2006 expected to initiate in 1H 2026, pending FDA feedback in Q2 2026.

• 12-month data update for high-dose LX2020 participants anticipated in Q4 2026; regulatory engagement with FDA expected in 2026.

• Operational runway projected into 2028 based on current cash resources.